Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Author Correction: Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes.

Rombaut D, Chiu HS, Decaesteker B, Everaert C, Yigit N, Peltier A, Janoueix-Lerosey I, Bartenhagen C, Fischer M, Roberts S, D'Haene N, De Preter K, Speleman F, Denecker G, Sumazin P, Vandesompele J, Lefever S, Mestdagh P.

Sci Rep. 2019 Jul 17;9(1):10536. doi: 10.1038/s41598-019-46785-6.

2.

Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.

Bellini A, Bessoltane-Bentahar N, Bhalshankar J, Clement N, Raynal V, Baulande S, Bernard V, Danzon A, Chicard M, Colmet-Daage L, Pierron G, Le Roux L, Planchon JM, Combaret V, Lapouble E, Corradini N, Thebaud E, Gambart M, Valteau-Couanet D, Michon J, Louis-Brennetot C, Janoueix-Lerosey I, Defachelles AS, Bourdeaut F, Delattre O, Schleiermacher G.

Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32361. [Epub ahead of print]

PMID:
31018240
3.

Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes.

Rombaut D, Chiu HS, Decaesteker B, Everaert C, Yigit N, Peltier A, Janoueix-Lerosey I, Bartenhagen C, Fischer M, Roberts S, D'Haene N, De Preter K, Speleman F, Denecker G, Sumazin P, Vandesompele J, Lefever S, Mestdagh P.

Sci Rep. 2019 Apr 5;9(1):5685. doi: 10.1038/s41598-019-42107-y. Erratum in: Sci Rep. 2019 Jul 17;9(1):10536.

4.

The sympathetic nervous system: malignancy, disease, and novel functions.

Huber K, Janoueix-Lerosey I, Kummer W, Rohrer H, Tischler AS.

Cell Tissue Res. 2018 May;372(2):163-170. doi: 10.1007/s00441-018-2831-0. No abstract available.

PMID:
29623426
5.

The ALK receptor in sympathetic neuron development and neuroblastoma.

Janoueix-Lerosey I, Lopez-Delisle L, Delattre O, Rohrer H.

Cell Tissue Res. 2018 May;372(2):325-337. doi: 10.1007/s00441-017-2784-8. Epub 2018 Jan 27. Review.

PMID:
29374774
6.

QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction.

Deveau P, Colmet Daage L, Oldridge D, Bernard V, Bellini A, Chicard M, Clement N, Lapouble E, Combaret V, Boland A, Meyer V, Deleuze JF, Janoueix-Lerosey I, Barillot E, Delattre O, Maris JM, Schleiermacher G, Boeva V.

Bioinformatics. 2018 Jun 1;34(11):1808-1816. doi: 10.1093/bioinformatics/bty016.

7.

Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.

Lopez-Delisle L, Pierre-Eugène C, Louis-Brennetot C, Surdez D, Raynal V, Baulande S, Boeva V, Grossetête-Lalami S, Combaret V, Peuchmaur M, Delattre O, Janoueix-Lerosey I.

Oncogene. 2018 Mar;37(11):1417-1429. doi: 10.1038/s41388-017-0039-5. Epub 2018 Jan 11.

8.

Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.

Chicard M, Colmet-Daage L, Clement N, Danzon A, Bohec M, Bernard V, Baulande S, Bellini A, Deveau P, Pierron G, Lapouble E, Janoueix-Lerosey I, Peuchmaur M, Corradini N, Defachelles AS, Valteau-Couanet D, Michon J, Combaret V, Delattre O, Schleiermacher G.

Clin Cancer Res. 2018 Feb 15;24(4):939-949. doi: 10.1158/1078-0432.CCR-17-1586. Epub 2017 Nov 30.

9.

Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival.

Brisse HJ, Blanc T, Schleiermacher G, Mosseri V, Philippe-Chomette P, Janoueix-Lerosey I, Pierron G, Lapouble E, Peuchmaur M, Fréneaux P, Galmiche L, Algret N, Peycelon M, Michon J, Delattre O, Sarnacki S.

PLoS One. 2017 Sep 25;12(9):e0185190. doi: 10.1371/journal.pone.0185190. eCollection 2017.

10.

Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries.

Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugène C, Raynal V, Etchevers HC, Thomas S, Lermine A, Daudigeos-Dubus E, Geoerger B, Orth MF, Grünewald TGP, Diaz E, Ducos B, Surdez D, Carcaboso AM, Medvedeva I, Deller T, Combaret V, Lapouble E, Pierron G, Grossetête-Lalami S, Baulande S, Schleiermacher G, Barillot E, Rohrer H, Delattre O, Janoueix-Lerosey I.

Nat Genet. 2017 Sep;49(9):1408-1413. doi: 10.1038/ng.3921. Epub 2017 Jul 24.

PMID:
28740262
11.

HMCan-diff: a method to detect changes in histone modifications in cells with different genetic characteristics.

Ashoor H, Louis-Brennetot C, Janoueix-Lerosey I, Bajic VB, Boeva V.

Nucleic Acids Res. 2017 May 5;45(8):e58. doi: 10.1093/nar/gkw1319.

12.

68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.

Provost C, Prignon A, Cazes A, Combaret V, Delattre O, Janoueix-Lerosey I, Montravers F, Talbot JN.

Anticancer Res. 2016 Sep;36(9):4459-66.

PMID:
27630282
13.

Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.

Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL.

Pediatr Blood Cancer. 2016 Jun;63(6):1019-23. doi: 10.1002/pbc.25934. Epub 2016 Feb 10.

14.

The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation.

Han ZY, Richer W, Fréneaux P, Chauvin C, Lucchesi C, Guillemot D, Grison C, Lequin D, Pierron G, Masliah-Planchon J, Nicolas A, Ranchère-Vince D, Varlet P, Puget S, Janoueix-Lerosey I, Ayrault O, Surdez D, Delattre O, Bourdeaut F.

Nat Commun. 2016 Jan 28;7:10421. doi: 10.1038/ncomms10421.

15.

SV-Bay: structural variant detection in cancer genomes using a Bayesian approach with correction for GC-content and read mappability.

Iakovishina D, Janoueix-Lerosey I, Barillot E, Regnier M, Boeva V.

Bioinformatics. 2016 Apr 1;32(7):984-92. doi: 10.1093/bioinformatics/btv751. Epub 2016 Jan 6.

16.

Lin28B and Let-7 in the Control of Sympathetic Neurogenesis and Neuroblastoma Development.

Hennchen M, Stubbusch J, Abarchan-El Makhfi I, Kramer M, Deller T, Pierre-Eugene C, Janoueix-Lerosey I, Delattre O, Ernsberger U, Schulte JB, Rohrer H.

J Neurosci. 2015 Dec 16;35(50):16531-44. doi: 10.1523/JNEUROSCI.2560-15.2015.

17.

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM.

Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29.

18.

Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.

Bellini A, Bernard V, Leroy Q, Rio Frio T, Pierron G, Combaret V, Lapouble E, Clement N, Rubie H, Thebaud E, Chastagner P, Defachelles AS, Bergeron C, Buchbinder N, Taque S, Auvrignon A, Valteau-Couanet D, Michon J, Janoueix-Lerosey I, Delattre O, Schleiermacher G.

Clin Cancer Res. 2015 Nov 1;21(21):4913-21. doi: 10.1158/1078-0432.CCR-15-0423. Epub 2015 Jun 9.

19.

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.

Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, Carter DR, Cazes A, Cheung BB, De Mariano M, De Bondt A, De Brouwer S, Delattre O, Gibbons J, Janoueix-Lerosey I, Laureys G, Liang C, Marchall GM, Porcu M, Takita J, Trujillo DC, Van Den Wyngaert I, Van Roy N, Van Goethem A, Van Maerken T, Zabrocki P, Cools J, Schulte JH, Vialard J, Speleman F, De Preter K.

Clin Cancer Res. 2015 Jul 15;21(14):3327-39. doi: 10.1158/1078-0432.CCR-14-2024. Epub 2015 Mar 24.

20.

Regulation by miR181 family of the dependence receptor CDON tumor suppressive activity in neuroblastoma.

Gibert B, Delloye-Bourgeois C, Gattolliat CH, Meurette O, Le Guernevel S, Fombonne J, Ducarouge B, Lavial F, Bouhallier F, Creveaux M, Negulescu AM, Bénard J, Janoueix-Lerosey I, Harel-Bellan A, Delattre O, Mehlen P.

J Natl Cancer Inst. 2014 Oct 13;106(11). pii: dju318. doi: 10.1093/jnci/dju318. Print 2014 Nov.

PMID:
25313246
21.

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M.

Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17.

22.

Recent insights into the biology of neuroblastoma.

Schleiermacher G, Janoueix-Lerosey I, Delattre O.

Int J Cancer. 2014 Nov 15;135(10):2249-61. doi: 10.1002/ijc.29077. Epub 2014 Aug 14. Review.

23.

Emergence of new ALK mutations at relapse of neuroblastoma.

Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, Pierron G, Lapouble E, Combaret V, Speleman F, de Wilde B, Djos A, Ora I, Hedborg F, Träger C, Holmqvist BM, Abrahamsson J, Peuchmaur M, Michon J, Janoueix-Lerosey I, Kogner P, Delattre O, Martinsson T.

J Clin Oncol. 2014 Sep 1;32(25):2727-34. doi: 10.1200/JCO.2013.54.0674. Epub 2014 Jul 28.

PMID:
25071110
24.

Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.

Guimier A, Ferrand S, Pierron G, Couturier J, Janoueix-Lerosey I, Combaret V, Mosseri V, Thebaud E, Gambart M, Plantaz D, Marabelle A, Coze C, Rialland X, Fasola S, Lapouble E, Fréneaux P, Peuchmaur M, Michon J, Delattre O, Schleiermacher G.

PLoS One. 2014 Jul 11;9(7):e101990. doi: 10.1371/journal.pone.0101990. eCollection 2014.

25.

Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells.

Montavon G, Jauquier N, Coulon A, Peuchmaur M, Flahaut M, Bourloud KB, Yan P, Delattre O, Sommer L, Joseph JM, Janoueix-Lerosey I, Gross N, Mühlethaler-Mottet A.

Oncotarget. 2014 Jun 30;5(12):4452-66.

26.

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.

Cazes A, Lopez-Delisle L, Tsarovina K, Pierre-Eugène C, De Preter K, Peuchmaur M, Nicolas A, Provost C, Louis-Brennetot C, Daveau R, Kumps C, Cascone I, Schleiermacher G, Prignon A, Speleman F, Rohrer H, Delattre O, Janoueix-Lerosey I.

Oncotarget. 2014 May 15;5(9):2688-702.

27.

Hyperactivation of Alk induces neonatal lethality in knock-in AlkF1178L mice.

Lopez-Delisle L, Pierre-Eugène C, Bloch-Gallego E, Birling MC, Duband JL, Durand E, Bourgeois T, Matrot B, Sorg T, Huerre M, Meziane H, Roux MJ, Champy MF, Gallego J, Delattre O, Janoueix-Lerosey I.

Oncotarget. 2014 May 15;5(9):2703-13.

28.

SegAnnDB: interactive Web-based genomic segmentation.

Hocking TD, Boeva V, Rigaill G, Schleiermacher G, Janoueix-Lerosey I, Delattre O, Richer W, Bourdeaut F, Suguro M, Seto M, Bach F, Vert JP.

Bioinformatics. 2014 Jun 1;30(11):1539-46. doi: 10.1093/bioinformatics/btu072. Epub 2014 Feb 3.

29.

Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsis.

Boeva V, Jouannet S, Daveau R, Combaret V, Pierre-Eugène C, Cazes A, Louis-Brennetot C, Schleiermacher G, Ferrand S, Pierron G, Lermine A, Rio Frio T, Raynal V, Vassal G, Barillot E, Delattre O, Janoueix-Lerosey I.

PLoS One. 2013 Aug 26;8(8):e72182. doi: 10.1371/journal.pone.0072182. eCollection 2013.

30.

Learning smoothing models of copy number profiles using breakpoint annotations.

Hocking TD, Schleiermacher G, Janoueix-Lerosey I, Boeva V, Cappo J, Delattre O, Bach F, Vert JP.

BMC Bioinformatics. 2013 May 22;14:164. doi: 10.1186/1471-2105-14-164.

31.

Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma.

Cazes A, Louis-Brennetot C, Mazot P, Dingli F, Lombard B, Boeva V, Daveau R, Cappo J, Combaret V, Schleiermacher G, Jouannet S, Ferrand S, Pierron G, Barillot E, Loew D, Vigny M, Delattre O, Janoueix-Lerosey I.

Cancer Res. 2013 Jan 1;73(1):195-204. doi: 10.1158/0008-5472.CAN-12-1242. Epub 2012 Nov 8.

32.

Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression.

Morales La Madrid A, Nall MB, Ouyang K, Minor A, Raca G, Kent P, Miller I, Schleiermacher G, Janoueix-Lerosey I, Cohn SL.

Pediatr Blood Cancer. 2013 Feb;60(2):332-5. doi: 10.1002/pbc.24311. Epub 2012 Sep 19.

PMID:
22997192
33.

Internalization and down-regulation of the ALK receptor in neuroblastoma cell lines upon monoclonal antibodies treatment.

Mazot P, Cazes A, Dingli F, Degoutin J, Irinopoulou T, Boutterin MC, Lombard B, Loew D, Hallberg B, Palmer RH, Delattre O, Janoueix-Lerosey I, Vigny M.

PLoS One. 2012;7(3):e33581. doi: 10.1371/journal.pone.0033581. Epub 2012 Mar 30.

34.

Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data.

Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, Janoueix-Lerosey I, Delattre O, Barillot E.

Bioinformatics. 2012 Feb 1;28(3):423-5. doi: 10.1093/bioinformatics/btr670. Epub 2011 Dec 6.

35.

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Bénard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Cañete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J.

Br J Cancer. 2011 Dec 6;105(12):1940-8. doi: 10.1038/bjc.2011.472. Epub 2011 Nov 10.

36.

ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.

Bourdeaut F, Ferrand S, Brugières L, Hilbert M, Ribeiro A, Lacroix L, Bénard J, Combaret V, Michon J, Valteau-Couanet D, Isidor B, Rialland X, Poirée M, Defachelles AS, Peuchmaur M, Schleiermacher G, Pierron G, Gauthier-Villars M, Janoueix-Lerosey I, Delattre O; Comité Neuroblastome of the Société Francaise de Cancérologie.

Eur J Hum Genet. 2012 Mar;20(3):291-7. doi: 10.1038/ejhg.2011.195. Epub 2011 Nov 9.

37.

Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition.

Reiff T, Huber L, Kramer M, Delattre O, Janoueix-Lerosey I, Rohrer H.

Development. 2011 Nov;138(21):4699-708. doi: 10.1242/dev.072157.

38.

Germline gain-of-function mutations of ALK disrupt central nervous system development.

de Pontual L, Kettaneh D, Gordon CT, Oufadem M, Boddaert N, Lees M, Balu L, Lachassinne E, Petros A, Mollet J, Wilson LC, Munnich A, Brugière L, Delattre O, Vekemans M, Etchevers H, Lyonnet S, Janoueix-Lerosey I, Amiel J.

Hum Mutat. 2011 Mar;32(3):272-6. doi: 10.1002/humu.21442.

PMID:
21972109
39.

[Genetic alterations in neuroblastoma and their usefulness for clinical management].

Normand C, Michon J, Janoueix-Lerosey I, Delattre O, Schleiermacher G.

Bull Cancer. 2011 May;98(5):477-88. doi: 10.1684/bdc.2011.1364. Review. French.

40.

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.

Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V, Hallberg B, Palmer RH, Delattre O, Janoueix-Lerosey I, Vigny M.

Oncogene. 2011 Apr 28;30(17):2017-25. doi: 10.1038/onc.2010.595. Epub 2011 Jan 17.

PMID:
21242967
41.

Control-free calling of copy number alterations in deep-sequencing data using GC-content normalization.

Boeva V, Zinovyev A, Bleakley K, Vert JP, Janoueix-Lerosey I, Delattre O, Barillot E.

Bioinformatics. 2011 Jan 15;27(2):268-9. doi: 10.1093/bioinformatics/btq635. Epub 2010 Nov 15.

42.

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.

De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F.

Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18.

43.

SVDetect: a tool to identify genomic structural variations from paired-end and mate-pair sequencing data.

Zeitouni B, Boeva V, Janoueix-Lerosey I, Loeillet S, Legoix-né P, Nicolas A, Delattre O, Barillot E.

Bioinformatics. 2010 Aug 1;26(15):1895-6. doi: 10.1093/bioinformatics/btq293.

44.

Prognostic impact of gene expression-based classification for neuroblastoma.

Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Vermeulen J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Weber A, Christiansen H, Grundy RG, Schardt K, Schwab M, Eils R, Warnat P, Kaderali L, Simon T, Decarolis B, Theissen J, Westermann F, Brors B, Fischer M.

J Clin Oncol. 2010 Jul 20;28(21):3506-15. doi: 10.1200/JCO.2009.27.3367. Epub 2010 Jun 21.

PMID:
20567016
45.

Accumulation of segmental alterations determines progression in neuroblastoma.

Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, Mosseri V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, Bourdeaut F, Combaret V, Bergeron C, Michon J, Delattre O.

J Clin Oncol. 2010 Jul 1;28(19):3122-30. doi: 10.1200/JCO.2009.26.7955. Epub 2010 Jun 1.

PMID:
20516441
46.

An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours.

Mestdagh P, Fredlund E, Pattyn F, Rihani A, Van Maerken T, Vermeulen J, Kumps C, Menten B, De Preter K, Schramm A, Schulte J, Noguera R, Schleiermacher G, Janoueix-Lerosey I, Laureys G, Powel R, Nittner D, Marine JC, Ringnér M, Speleman F, Vandesompele J.

Oncogene. 2010 Jun 17;29(24):3583-92. doi: 10.1038/onc.2010.106. Epub 2010 Apr 12.

PMID:
20383195
47.

Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature.

De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, Nakagawara A, Oberthuer A, Ohira M, Schleiermacher G, Schramm A, Schulte JH, Wang Q, Westermann F, Speleman F, Vandesompele J.

Clin Cancer Res. 2010 Mar 1;16(5):1532-41. doi: 10.1158/1078-0432.CCR-09-2607. Epub 2010 Feb 23.

48.

Molecular pathogenesis of peripheral neuroblastic tumors.

Janoueix-Lerosey I, Schleiermacher G, Delattre O.

Oncogene. 2010 Mar 18;29(11):1566-79. doi: 10.1038/onc.2009.518. Epub 2010 Jan 25. Review.

PMID:
20101209
49.

Cholinergic switch associated with morphological differentiation in neuroblastoma.

Bourdeaut F, Janoueix-Lerosey I, Lucchesi C, Paris R, Ribeiro A, de Pontual L, Amiel J, Lyonnet S, Pierron G, Michon J, Peuchmaur M, Delattre O.

J Pathol. 2009 Dec;219(4):463-72. doi: 10.1002/path.2614.

PMID:
19768740
50.

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.

Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Cañete A, Castel V, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Bénard J, Marques B, Rubie H, Kohler J, Pötschger U, Ladenstein R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J.

Lancet Oncol. 2009 Jul;10(7):663-71. doi: 10.1016/S1470-2045(09)70154-8. Epub 2009 Jun 8.

Supplemental Content

Loading ...
Support Center